PMID- 33502688
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20220304
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 38
IP  - 3
DP  - 2021 Mar
TI  - Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and 
      Meta-Analysis.
PG  - 1483-1513
LID - 10.1007/s12325-021-01620-1 [doi]
AB  - INTRODUCTION: Micro- and macrovascular complications of diabetes are leading 
      morbidities in the world population. They are responsible not only for increased 
      mortality but also severe disabilities, which jeopardize quality of life (e.g., 
      blindness, walking limitations, and renal failure requiring dialysis). The new 
      antidiabetic agents (e.g., glucagon-like peptide 1 receptor agonists and 
      sodium-glucose cotransporter inhibitors) are increasingly recognized as 
      breakthrough agents in the treatment of diabetes and prevention of diabetic 
      complications. However, drugs effective in preventing and treating diabetic 
      disabilities are still needed and sulodexide could be one of those able to 
      address the unmet clinical needs of the new antidiabetic agents. METHODS: We 
      searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and 
      the World Health Organization (WHO) International Clinical Trials Registry 
      Platform Search Portal. We also manually searched potentially relevant journals, 
      conference proceedings, and journal supplements. Any study monitoring any effect 
      of sulodexide in subjects with diabetes, in relation to renal, vascular, and 
      ocular complication, was considered. Treatment effects were estimated using 
      standardized mean differences (SMDs), mean differences (MDs), and risk ratios 
      (RRs), as appropriate. We calculated 95% confidence interval (CIs) and 
      heterogeneity (Q, tau, and I(2)). RESULTS: The search found 45 studies with 2817 
      participants (mean age 57 years; 63% male). The 26 randomized controlled studies 
      included 2074 participants (mean age 58.8 years; 66% male). Sulodexide reduced 
      the impact of diabetic retinopathy; increased the pain-free and maximal walking 
      distance in peripheral arterial disease; accelerated the healing of 
      diabetes-associated trophic ulcers; and decreased the rate of albumin excretion 
      in subjects with nephropathy. The risk of adverse events (AEs) was not different 
      between sulodexide and controls. CONCLUSION: Sulodexide has a beneficial effect 
      on the ocular, peripheral arterial disease, trophic ulcers, and renal 
      complications of diabetes without increasing the risk of AEs.
FAU - Bignamini, Angelo A
AU  - Bignamini AA
AUID- ORCID: 0000-0002-4410-1511
AD  - School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical 
      Sciences, University of Milan, Milan, Italy. angelo@aabignamini.it.
FAU - Chebil, Ahmed
AU  - Chebil A
AD  - Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of 
      Medicine of Tunis, University of El Manar, Tunis, Tunisia.
FAU - Gambaro, Giovanni
AU  - Gambaro G
AD  - Division of Nephrology and Dialysis, Ospedale Maggiore, University of Verona, 
      Verona, Italy.
FAU - Matuska, Jiri
AU  - Matuska J
AD  - MATMED S.R.O., Private Angiology Facility, Hodonin, Czech Republic.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210127
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Hypoglycemic Agents)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
MH  - *Diabetes Mellitus
MH  - Female
MH  - Glycosaminoglycans/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
PMC - PMC7932977
OTO - NOTNLM
OT  - Claudication
OT  - Diabetes complications
OT  - Diabetes-associated trophic ulcers
OT  - Efficacy
OT  - Meta-analysis
OT  - Nephropathy
OT  - Peripheral arterial disease
OT  - Retinopathy
OT  - Sulodexide
EDAT- 2021/01/28 06:00
MHDA- 2021/04/15 06:00
PMCR- 2021/01/27
CRDT- 2021/01/27 12:17
PHST- 2020/12/07 00:00 [received]
PHST- 2021/01/06 00:00 [accepted]
PHST- 2021/01/28 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2021/01/27 12:17 [entrez]
PHST- 2021/01/27 00:00 [pmc-release]
AID - 10.1007/s12325-021-01620-1 [pii]
AID - 1620 [pii]
AID - 10.1007/s12325-021-01620-1 [doi]
PST - ppublish
SO  - Adv Ther. 2021 Mar;38(3):1483-1513. doi: 10.1007/s12325-021-01620-1. Epub 2021 
      Jan 27.